Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Discov. 2023 Mar 1;13(3):580–597. doi: 10.1158/2159-8290.CD-22-0964

Fig. 3. Patients refractory to multiple prior lines of treatment respond to CART19/20 cell therapy.

Fig. 3.

Timeline of individual patients’ response to prior treatment and to CART19/20 cell therapy. The disease indication and dose of CART19/20 cells received are also indicated for each patient. Light green box for patient 009 post CAR-T cell infusion denotes time between the last CR confirmed by PET scan and the time of patient death. The patient had no detectible lymphoma based on IHC analysis performed on bone-marrow biopsy shortly before death due to grade-5 hypocellular marrow. MCL, mantle-cell lymphoma; FL, follicular lymphoma; PMBCL, primary mediastinal B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; tFL, transformed follicular lymphoma; HGBCL dh, high-grade B-cell lymphoma double-hit.